Third Ordinary General Meeting of Shareholders of Basilea Pharmaceutica AG
01. Juni 2004 12:06 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, June 1, 2004 (PRIMEZONE) -- In his presentation to shareholders today, Anthony Man MD, Basilea's CEO, reflected on the 2003 business year as follows:
"We achieved our ambitious...
Basilea Gains Global Commercialization Rights for BAL5788, a Novel First-In-Class Antibiotic
25. Mai 2004 01:33 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, May 25, 2004 (PRIMEZONE) -- Basilea Pharmaceutica today announced gaining the global marketing and manufacturing rights for BAL5788 following Roche's decision not to exercise its...
Basilea's Antibiotic BAL5788 - Unlikely to Induce Resistance in MRSA
03. Mai 2004 11:50 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, May 03, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG presented in vitro data yesterday at the 14th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID),...
Positive Phase II Results for Basilea's Novel First-In-Class Antibiotic
03. März 2004 01:39 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, March 3, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG today announced positive phase II results for BAL5788 in the indication of complicated skin and skin structure infections...
Basilea Pharmaceutica AG Successfully Completes Phase I Development for BAL8557, a New Broad-Spectrum Oral and Intravenous Antifungal
24. Februar 2004 11:40 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Feb. 24, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG today announced the successful completion of phase I development for BAL8557, a novel water-soluble azole suitable for both...
BASILEA continues to strengthen research and development
12. Februar 2004 10:54 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Feb. 12, 2004 (PRIMEZONE) -- Pharmaceutica Ltd announced today that it has appointed Professor Jutta Heim as Chief Scientific Officer and Dr. Ingrid Heinze-Krauss as Chief...
Basilea Announces Positive Phase II Results of BAL4079 (Alitretinoin) in Refractory Chronic Hand Dermatitis
21. März 2003 07:21 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, March 21, 2003 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. announced today that its double-blind, placebo-controlled, randomized, dose finding study of BAL4079 in patients with...
FDA Fast Track Designation for Basilea's Novel Broad Spectrum Antibiotic
10. März 2003 04:16 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, March, 10, 2003 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. today announced that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for its...